ALLISON--Anthony Clifford, passed away on February 20, 2014 at 88 at his aerie overlooking San Francisco Bay in Belmont, California. Born and raised in Africa, Tony studied medicine at Oxford, and dedicated his life to medical research. He is best known for demonstrating that humans carrying the sickle cell trait are resistant to Plasmodium falciparum malaria (1953), representing the first recognized example of Darwinian selection in humans. At Syntex in Palo Alto, CA, in collaboration with his second wife Elsie and many other scientists, he developed his concept of a novel immunosuppressive drug. The successful development of CellCept has dramatically improved the long-term survival of patients with transplanted organs, and autoimmune diseases such as systemic lupus. CellCept became one of Roche's blockbuster drugs. He covered many fields of research, and published more than 400 papers in peer reviewed journals. Many were citation classics. He is survived by his second wife and professional partner Elsie Eugui, his two sons in the UK (from his first marriage to Helen Green), Miles and Joseph Mark, a half sister, Colleen, and half brother Roy in South Africa, and numerous nieces, nephews, cousins, and friends in different countries. An avid reader with an extraordinary memory, Tony was passionate about nature, including deep-sea fishing, hiking, bird-watching, classical music and wine tasting, all of which he shared with Elsie and imparted to his sons. Tony will be sorely missed, and remembered by friends, collaborators, and family for his boundless intellectual energy, creativity, many contributions to science, work ethic, and his human qualities. A celebration of his life will be held on April 13. Time and location will be found at www.crippenflynn.com or through Elsie at firstname.lastname@example.org. In lieu of flowers, donations may be made to
, Sierra Club, or any charity desired.
The Guest Book is expired.
Crippen & Flynn Carlmont Chapel (FD1825)
1111 Alameda de las Pulgas Belmont, CA 94002
Published in The New York Times on Mar. 2, 2014